Project|21 is a new initiative created by SENS Research Foundation to advance rejuvenation biotechnology to human clinical trials by 2021, through three complementary programs: the Bridge Fund, the Center of Excellence, and the Alliance Program.

Join Aubrey de Grey, Chief Science Officer of the SENS Research Foundation, on a tour of our Research Center in Mountain View, CA, and learn more about our Control ALT, Delete Cancer campaign. Filmed in 360-degree virtual reality!

In a new half-hour podcast, the Methuselah Foundation's Rod Wheaton interviews SRF researchers Dr. Haroldo Silva and David Halvorsen about the goals of our Control ALT, Delete Cancer crowdfunding campaign.

Internet entrepreneur Michael Greve is the first donor to our new Project|21 campaign, with a gift of $5 million towards SENS research programs. Michael has also pledged a further $5 million in seed funding for startups in the field of rejuvenation biotechnology.

Check out all the latest news from SENS Research Foundation in our August newsletter. You might also like to check out the archive of past messages, or subscribe to our mailing list to make sure you don't miss out on future updates!

Veteran longevity science blogger Reason highlights the significance of SRF's new Control ALT, Delete Cancer campaign within the broader context of cancer research, and interviews lead researcher Dr. Haroldo Silva.

13-year-old Bradley put his questions about aging to Dr. Aubrey de Grey for Kidspiration.tv, a new online channel created for kids. The interview is a great way to explain to your children (and maybe your parents) what SRF is working to achieve!

Entrepreneur and biohacker Dave Asprey recently interviewed our Chief Science Officer, Dr. Aubrey de Grey, for the health podcast Bulletproof Radio. Their in-depth conversation covers a broad range of topics related to our current work and future plans.

SENS Research Foundation extends congratulations to our collaborators at the Albert Einstein College of Medicine, who have published an open-access paper in Genome Biology detailing some of the work SENS Research Foundation has funded.

SENS Research Foundation is pleased to announce our new crowdfunding campaign in collaboration with Lifespan.io, raising funds to test drugs against some of the most deadly cancers. We've just issued a press release with much more detail on the campaign.

SENS Research Foundation's work is the subject of the latest volume in Zero Books' series Advancing Conversations. Available now, the book documents a series of interviews with Dr. de Grey covering recent progress and our responses to critics.

Shopping online this summer? When you use our Amazon Smile link, Amazon automatically donates part of your payment to SRF - and it won't cost you an extra cent!

See the SRF Summer Scholars Program through the eyes of the Summer Scholars themselves. Shot entirely by the students, this video not only highlights the 2015 host research institutions and a few of the labs but also the camaraderie of the experience.

Our general introduction to SENS research, Ending Aging, is now available in audiobook format. All profits will go to SENS Research Foundation. If Ending Aging is your first purchase as a new Audible member, we also get a $50 "bounty" - so please consider signing up!

A new article in Genetic Engineering & Biotechnology News explores how applying regenerative medicine to the accumulated damage of aging is becoming an increasingly mainstream idea, crediting SRF CSO Aubrey de Grey as a pioneer in the field.

For the second year in a row, SENS Research Foundation has been recognised as a Top-Rated Nonprofit by GreatNonprofits.org - the only people's choice award in the nonprofit sector. Our thanks go out to everyone whose reviews helped us earn the award!

Our CSO Dr. Aubrey de Grey, and Buck Institute for Research on Aging CEO Brian Kennedy, successfully opposed the motion that "Lifespans Are Long Enough" in debate at the Kaufman Center on February 3rd. A full video of the debate is now available.

An SRF-funded study by Yale University Professor David Spiegel has been published in world-leading journal Science. The discoveries announced will accelerate future research in the fields of diabetes and age-related tissue cross-linking.